Prospective Evaluation of Circulating Tumor DNA Using Next-generation Sequencing as a Biomarker During Neoadjuvant Chemotherapy in Localized Pancreatic Cancer

Abstract excerpt

OBJECTIVE: In this prospective study, we aim to characterize the prognostic value of circulating tumor DNA (ctDNA) by next-generation sequencing (NGS) in patients undergoing neoadjuvant chemotherapy (NAC) for pancreatic ductal adenocarcinoma (PDAC). BACKGROUND: ctDNA is a promising blood-based biomarker that is prognostic in several malignancies. Detection of ctDNA by NGS may provide insights regarding the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Cells and Metastasis
• Share to Cancer Genomics and Diagnostics
• Share to Pancreatic and Hepatic Oncology Research